Arcturus Therapeutics vs ProQR Therapeutics
ARCT and PRQR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARCT and PRQR compare
ProQR Therapeutics grew revenue faster over the last twelve months (11.4% versus −68.7% for Arcturus Therapeutics).
ProQR Therapeutics keeps more of each dollar of sales as profit, with a net margin of −229% compared with −286% at Arcturus Therapeutics.
Arcturus Therapeutics scores higher on the StockData Score (9 against 6 for ProQR Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARCT | PRQR |
|---|---|---|
| Size and price | ||
| Market cap | $238M | – |
| Share price | $8.36 | $1.41 |
| Change, 1 year | 2.8% | −34.7% |
| Change, 5 years | −77.1% | −81.9% |
| Beta (5Y) | 2.16 | 1.26 |
| Employees | 111 | 59 |
| StockData Score | ||
| Total score | 9 (better) | 6 |
| Valuation score | 2 (better) | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 2 (better) | 1 |
| Health score | 5 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 7.8× | – |
| P/B | 1.4× | – |
| FCF yield | −26.3% | – |
| Fair value | $8.63 | – |
| Margin of safety | 3.1% | – |
| Growth | ||
| Revenue growth (TTM) | −68.7% | 11.4% (better) |
| Revenue growth, 5Y average | 53.8% | – |
| Profitability | ||
| Operating margin | −311% | −233% (better) |
| Net margin | −286% | −229% (better) |
| FCF margin | −205% (better) | −273% |
| Return on equity | −44.4% (better) | −57.4% |
| Return on invested capital | −534% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.06 (better) |
| Current ratio | 6.68 (better) | 3.49 |
| Altman Z-score | −1.08 | – |
| Piotroski F-score | 2 (better) | 1 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 87.9% | 57.6% |
| Held by insiders | 8.1% | 37.8% |
| Insider net buying, 12 months | – | $1.3M |
| Short interest, % of float | 20.7% | – |
Go deeper
- ARCT stock overview
- ARCT income statement
- ARCT valuation and score
- PRQR stock overview
- PRQR income statement
- PRQR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.